An infant monitor can display a result. What a caregiver should do with that result is part of the device's safety, too.
That is the most revealing requirement in an FDA order published October 9. It codifies the existing class II classification for infant pulse-rate and oxygen-saturation monitors for over-the-counter use, with special controls. Among those controls, human-factors testing must demonstrate that a caregiver can use the device from its labeling, interpret its output and understand the next steps.
The person reading the number is inside the safety requirement. A good sensor is not the whole product.
The rule includes the person at the other end
The order describes devices that measure pulse rate and oxygen saturation using an optical signal. They may have alarms when a vital sign crosses a preset threshold. Its risk table includes inadequate signals, false positives, false negatives and tissue reactions. It also names misinterpretation or over-reliance on the output that could lead someone to fail to seek treatment despite acute symptoms.
That last risk matters because a display can look precise without explaining its limits. An alarm can tell someone to pay attention. Silence can be easier to misunderstand. The rule does not treat that misunderstanding as something outside the manufacturer's concern.
The required labeling must explain the intended population, populations where the device should not be used, what it measures, how to interpret results and what actions are appropriate. It must also name situations where performance may fall short of expectations. Clinical testing must examine relevant conditions of use, including the effect of skin pigmentation on performance.
These are requirements in the order, not results from an independent examination of a monitor. They make a useful reading list for the claim itself: whose measurements, under what conditions, with what limitations, and with what response expected from the person looking at them?
Authorization has a subject
The classification's two dates deserve care. The order is effective October 9, 2026; the classification was applicable November 8, 2023. FDA says it is codifying the earlier classification arising from Owlet Baby Care's Dream Sock request. The publication does not turn every infant monitor on sale into an authorized medical device.
It also does not remove the premarket-notification requirement for this device type. The order explains that FDA has not exempted the category from that requirement. A classification creates a regulatory route and identifies controls. It is not a blanket endorsement of a shelf of products.
FDA's separate September 16, 2025 safety communication draws another boundary. The agency warns against unauthorized infant vital-sign monitors and describes risks from inaccurate readings and missed changes. It says no device, including an infant monitor, has been authorized to prevent sudden infant death syndrome (SIDS) or sudden unexpected infant death (SUID). The communication also says infant monitors do not replace adult supervision or safe-sleep practices.
Those statements do not dismiss authorized devices or their intended uses. They place a limit on the promise. Permission to measure particular vital signs cannot be read as permission to claim prevention of sudden infant death.
Read the promise as carefully as the number
The temptation is to let an official status answer a larger question than it was issued to answer. Class II is a classification. Authorization has an intended use. A number has a measurement behind it. None of those terms, by itself, promises an outcome outside that use.
The October 9 order is unusually concrete about the boundary: interpreting the output and understanding the next step must be tested. The display is a link in a chain that ends with a person making a decision. The device's limitations belong in that chain, where the person can see them.
The strongest claim here is therefore also the narrower one. A device may be useful for its authorized purpose. That purpose should survive the journey from the regulatory document to the package, to the advertisement, to the tired person reading the screen.
The number is information. The promise still needs evidence of its own.
Source links
- FDA infant pulse-rate and oxygen-saturation monitor classification, October 9, 2026 — Federal Register full text, FR Doc. 2026-20726
- Published Government Publishing Office PDF of the classification and special controls
- FDA, Do Not Use Unauthorized Infant Devices for Monitoring Vital Signs, September 16, 2025 safety communication
- Reporting: infant monitor classification and caregiver interpretation requirements